相似文献
1
New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?
Oncologist. 2014 Dec;19(12):1291. doi: 10.1634/theoncologist.2014-0263.
2
Optional copayments on anti-cancer drugs.
BMJ. 2013 Jan 24;346:f349. doi: 10.1136/bmj.f349.
3
A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
J Oncol Pharm Pract. 2012 Mar;18(1):57-67. doi: 10.1177/1078155210390724. Epub 2011 Mar 7.
4
Should the cost of care for patients with glioblastoma influence treatment decisions?
Continuum (Minneap Minn). 2012 Apr;18(2):416-20. doi: 10.1212/01.CON.0000413667.65668.ae.
5
NICE confirms advanced breast cancer drug is too expensive for NHS.
BMJ. 2014 Aug 7;349:g5078. doi: 10.1136/bmj.g5078.
6
Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
Oncologist. 2010;15 Suppl 1:49-57. doi: 10.1634/theoncologist.2010-S1-49.
7
Shortening the infusion time of anticancer drugs: who will benefit?
J Clin Oncol. 2007 Jul 1;25(19):2642-3. doi: 10.1200/JCO.2007.10.7334.
8
NICE says drug for metastatic breast cancer is unaffordable for NHS.
BMJ. 2014 Apr 22;348:g2888. doi: 10.1136/bmj.g2888.
9
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Am J Clin Oncol. 2009 Oct;32(5):492-8. doi: 10.1097/COC.0b013e3181931277.
10
Do oncologists believe new cancer drugs offer good value?
Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90.
引用本文的文献
1
Editorial: Multimodal management of advanced gastric cancer.
Front Oncol. 2022 Dec 29;12:1113856. doi: 10.3389/fonc.2022.1113856. eCollection 2022.
2
Redefining the Treatment Endpoints in Oncology.
Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.
3
Social taboos: a formidable challenge in cancer care.
BMJ Case Rep. 2021 Jan 11;14(1):e236095. doi: 10.1136/bcr-2020-236095.
4
Hyperthermic Intraperitoneal Chemotherapy - Fading Perspective in the Light of Modern Systemic Chemotherapy?
Visc Med. 2018 Dec;34(6):412-416. doi: 10.1159/000493493. Epub 2018 Oct 30.
5
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Ann Oncol. 2017 Nov 1;28(11):2633-2647. doi: 10.1093/annonc/mdx521.
本文引用的文献
1
Quality of life in the trastuzumab for gastric cancer trial.
Oncologist. 2014 Jul;19(7):712-9. doi: 10.1634/theoncologist.2014-0058. Epub 2014 Jun 20.
2
Delivery of affordable and equitable cancer care in India.
Lancet Oncol. 2014 May;15(6):e223-33. doi: 10.1016/S1470-2045(14)70117-2. Epub 2014 Apr 11.
3
Cancer drugs in the United States: Justum Pretium--the just price.
J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. Epub 2013 May 6.
4
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04.
5
Insured yet vulnerable: out-of-pocket payments and India's poor.
Health Policy Plan. 2012 May;27(3):213-21. doi: 10.1093/heapol/czr029. Epub 2011 Apr 12.
6
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
7
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
8
Medical bankruptcy in the United States, 2007: results of a national study.
Am J Med. 2009 Aug;122(8):741-6. doi: 10.1016/j.amjmed.2009.04.012. Epub 2009 Jun 6.
Zotero 插件